Supplementary Table 2 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602044

2024-01-01

Abstract:Supplementary Table 2. Known Cancer-testis antigen genes used in this study.

What problem does this paper attempt to address?

Supplementary Table 1 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602047

2024-01-01

Abstract:Supplementary Table 1. A summary of the clinical trial datasets used in this study.
Supplementary Figure 9 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602053

2024-01-01

Abstract:Supplementary Figure 9. Sensitivities and positive predictive values of TAA burden at different cut points in TCC tumors with unelevated CD8 S3 state in the IMvigor210 (a) and UNC datasets (b).
Supplementary Figure 4 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602068

2024-01-01

Abstract:Supplementary Figure 4. HEPA based TAB better-prioritized responders in the IC0 group of the IMVigor210 urothelial carcinoma cohort than known CTA burden (left) and FMOne tumor mutation burden (right).
Supplementary Figure 1 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602092

2024-01-01

Abstract:Supplementary Figure 1. The pathological response rates of patients from different IC groups in the IMVigor210 trial.
Supplementary Figure 5 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602065

2024-01-01

Abstract:Supplementary Figure 5. The distribution of Ecotyper CD8 T cell S3, epithelial cell S4, and dendritic cell S3 scores in different Lund2 and TCGA molecular subtypes of urothelial carcinomas of the IMVigor210 dataset. TAA burdens are shown as color gradient. P-values are based on two-tailed Welch’s T test. *, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001.
Supplementary Figure 8 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602056

2024-01-01

Abstract:Supplementary Figure 8. Correlation between TMB (FoundationOne) and Ecotyper CD8 S3 signature in urothelial carcinoma of the IMVigor210 patient cohort.
Supplementary Figure 14 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602077

2024-01-01

Abstract:Supplementary Figure 14. Receiver operating characteristic curves of TAA and CTA burdens and TMB for predicting ICB benefits in a retrospective patient cohort treated with anti-PD1 immune checkpoint inhibition (Liu et al. Nature Medicine 2019). (a) The predictive value of TAB, CTB, and TMB in the overall cohort stratified by CD8 S3 and TMB levels. (b) The predictive value of TAB, CTB, and TMB in the patient cohort that did not receive steroids, stratified by CD8 S3 and TMB levels.
Supplementary Figure 10 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602089

2024-01-01

Abstract:Supplementary Figure 10. Associations of TAA and CTA burdens with progression-free survival (PFS) and overall survival (OS) in the TCGA bladder cancer dataset. (a) Association of TAA burden with patient survival in the TCGA bladder cancer dataset. (b) Association of CTA burden with patient survival in the TCGA bladder cancer dataset. Patients are stratified based on Ecotyper CD8 S3 scores (median + median absolute deviation). The p-values are calculated based on log rank tests.
Supplementary Figure 6 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602062

2024-01-01

Abstract:Supplementary Figure 6. Two-dimensional density plots showing the correlation between Ecotyper CD8 T cell S3 state with T cell exhaustion (a) and T effector signatures (b).
Supplementary Figure 11 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602086

2024-01-01

Abstract:Supplementary Figure 11. TAA burden in responders and non-responders of nivolumab treatment in HNSC patients stratified based on Ecotyper CD8 S3 scores. Figure shows the patients from a neoadjuvant trial of advanced-stage HNSC patients treated with the anti-PD-1 antibody nivolumab (Obradovic dataset). P-values are based on one-tailed Welch’s T test.
Supplementary Figure 12 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602083

2024-01-01

Abstract:Supplementary Figure 12. The receiver operating characteristic curves of TAA burden and CTA burden for predicting ICB benefits in two HNSC ICB clinical trial datasets. Left panel shows a neoadjuvant trial of advanced-stage HNSC patients treated with the anti-PD-1 antibody nivolumab (Obradovic dataset). Right panel shows patients recruited for a neoadjuvant pembrolizumab trial (Uppaluri dataset). All patient subjects in the two trials are included in the analyses.
Supplementary Figure 7 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602059

2024-01-01

Abstract:Supplementary Figure 7. Three-way interactions between TMB, Ecotyper CD8 S3 signature, and the association of TAB with ICB benefit in urothelial carcinoma patients of the IMVigor210 cohort. a) Johnson-Neyman plot showing the correlation of the slope of TAB with Ecotyper signature of exhausted CD8 T cell (S3) in patient subjects stratified based on median TMB levels. b) Johnson-Neyman plot showing the correlation of the slope of TAB with foundation one TMB in patient subjects stratified based on Ecotyper CD8 S3 signature (high vs unelevated). The y-axis shows the slope of TAB, which is calculated based on its slope of correlation with binary responses (CR/PR vs SD/PD).
Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion.

Yue Wang,Mengying Hu,Olivera J Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.cir-23-0932

IF: 10.1

2024-01-01

Cancer Immunology Research

Abstract:Tumor-associated antigens (TAAs) are important targets for cancer vaccines. However, TAA-based vaccines have not yet achieved their full potential in clinical trials. In contrast, immune checkpoint blockade (ICB) has emerged as an effective therapy, leading to durable responses in selected cancer patients. To date, few generalizable associations between TAAs and ICB benefit have been reported, with most studies focusing on melanoma that has the highest mutation rate in cancer. In this study, we developed a TAA burden (TAB) algorithm based on known and putative TAAs and investigated the association of TAB with ICB benefit. Analysis of the IMVigor210 patient cohort of urothelial carcinoma treated with anti-PD-L1 revealed that high tumor mutation burden (TMB) weakened the association of TAB with ICB benefit. Furthermore, TAB correlated with ICB efficacy in tumors characterized by negative PD-L1 staining on immune cells, while high levels of PD-L1 staining on immune cells were linked to T-cell exhaustion. Validation across independent clinical datasets—including urothelial carcinoma cohorts treated with anti-PD1/PD-L1 agents and neoadjuvant anti-PD1 trials for head and neck cancers—corroborated the finding that TAB correlates with ICB benefit in tumors with low T-cell exhaustion. Pan-cancer analyses revealed that in most cancer entities, tumors with higher T-cell exhaustion exhibited lower TAB levels, implying possible immunoediting of TAAs in tumors with established antitumor immunity. Our study challenges the prevailing notion of a lack of association between TAAs and ICB response. It also underscores the need for future investigations into the immunogenicity of TAAs and TAA-based vaccine strategies in tumors with low levels of T-cell exhaustion.
Supplementary Figure 3 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602071

2024-01-01

Abstract:Supplementary Figure 3. The p-values for TAB, CTB, TMB, molecular subtypes, and clinical variables in the multivariate models containing all variables when the effects from other variables are removed. (a) Patient subjects of the IC0 group in the IMVigor210 cohort. (b) Patient subjects of the IC1-2+ group in the IMVigor210 cohort. The p-value of the coefficient of each variable is calculated by ANOVA. The left panel shows multivariate logistic regression to model binary response, adjusting for the presence of other covariates. The right panel shows multivariate Cox proportional hazard regression to model overall survival. Patient subjects stratified by IC0 or IC1-2+ groups in the IMVigor210 cohort are included in the analyses. A type-II ANOVA is applied to the fitted logistic regression or Cox proportional hazard regression models to evaluate the significance of each covariate independently, ensuring that the unique contribution of each marker is assessed in the presence of others. The analysis highlights the relative importance of each marker, with p-values indicating their individual contributions to predicting binary response, after accounting for confounding effects from the other variables.
Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Jiefei Han,Jianchun Duan,Hua Bai,Yuqi Wang,Rui Wan,Xin Wang,Si Chen,Yanhua Tian,Di Wang,Kailun Fei,Zhuoran Yao,Shuhang Wang,Zhimin Lu,Zhijie Wang,Jie Wang

DOI: https://doi.org/10.1158/2326-6066.22543059.v1

2023-01-01

Abstract:Univariable and multivariable analysis of progression-free survival (PFS).
Low Mutation Burden and Differential Tumor-Infiltrating Immune Cells Correlate with Lymph Node Metastasis in Colorectal Cancer

Xiao Huang,Wei Cai,Li Liu,Wenliang Yuan

2020-01-01

Abstract:Background: Tumor immunotherapy has become an important means of cancer treatment. A response depends on the interaction of tumor cells with immune regulators in the tumor microenvironment, which plays an important role in inhibiting or enhancing the immune response. However, lymph node (LN) metastasis leads to major changes in the tumor microenvironment of patients with colorectal cancer, directly affecting prognosis. Methods: Using data downloaded from the Cancer Genome Atlas (TCGA) database, we studied the microenvironmental differences between LN-negative and positive populations by bioinformatic methods. Results: Patients in the LN-positive group had significantly lower immune scores, cytolytic activity scores, and overall survival than the LN-negative group. In addition, a high mutation burden and a new antigen burden could inhibit lymph node metastasis of CRC. In particular, in the LN positive group, the ratio of monocytes to M1 macrophages was significantly downregulated. After the differentially expressed mRNAs between the LN positive and negative groups were determined, a new CRC model was constructed based on multivariate Cox proportional hazard regression analysis to examine the prognosis of patients. The analyses showed that the model was stable and robust. Conclusions: We used multiple scores and details of immune cell infiltration as indicators to assess changes in the tumor microenvironment of CRC patients before and after lymph node metastasis, and quantify and model the immune cells in the microenvironment to predict the overall survival of CRC patients.
Table S2 from Spatial Context of Immune Checkpoints As Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages

Hao Kong,Qingxin Yang,Chunwei Wu,Xiangji Wu,Xinrui Yan,Li-Bin Huang,Lu Chen,Zong-Guang Zhou,Ping Wang,Hong Jiang

DOI: https://doi.org/10.1158/2767-9764.27908031

2024-01-01

Abstract:Clinical characteristics of patients from TMA study
Supplementary Tables from Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity

Dapeng Hao,Jie Liu,Meng Chen,Jingjing Li,Li Wang,Xiaobo Li,Qi Zhao,Lijun Di

DOI: https://doi.org/10.1158/1078-0432.22470641.v1

2023-01-01

Abstract:Supplementary Table 1 and Supplementary Table 2
Supplementary Table 3 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Qing-Wen Xu,Wei Zhao,Yue Wang,Maureen A. Sartor,Dong-Mei Han,Jixin Deng,Rakesh Ponnala,Jiang-Ying Yang,Qing-Yun Zhang,Guo-Qing Liao,Yi-Mei Qu,Lu Li,Fang-Fang Liu,Hong-Mei Zhao,Yan-Hui Yin,Wei-Feng Chen,Yu Zhang,Xiao-Song Wang

DOI: https://doi.org/10.1158/0008-5472.22394703

2023-01-01

Abstract:PDF file - 104K, Literature references reporting the clinical applications of known TSAs and the top 100 genes nominated by HEPA analysis
Supplementary Table 2 from An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer

Qing-Wen Xu,Wei Zhao,Yue Wang,Maureen A. Sartor,Dong-Mei Han,Jixin Deng,Rakesh Ponnala,Jiang-Ying Yang,Qing-Yun Zhang,Guo-Qing Liao,Yi-Mei Qu,Lu Li,Fang-Fang Liu,Hong-Mei Zhao,Yan-Hui Yin,Wei-Feng Chen,Yu Zhang,Xiao-Song Wang

DOI: https://doi.org/10.1158/0008-5472.22394706

2023-01-01

Abstract:PDF file - 41K, The weights for normal adult somatic tissues for the calculation of Depreciatory Penalty score

Supplementary Table 2 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Table 1 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 9 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 4 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 1 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 5 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 8 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 14 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 10 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 6 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 11 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 12 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 7 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion.

Supplementary Figure 3 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Low Mutation Burden and Differential Tumor-Infiltrating Immune Cells Correlate with Lymph Node Metastasis in Colorectal Cancer

Table S2 from Spatial Context of Immune Checkpoints As Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages

Supplementary Tables from Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity

Supplementary Table 3 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 2 from An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer